An exploratory study for development of neurophysiological indicators for prediction and evaluation of effectiveness of serotonin reuptake inhibitor fluvoxamine in patients with major depressive disorder

Trial Profile

An exploratory study for development of neurophysiological indicators for prediction and evaluation of effectiveness of serotonin reuptake inhibitor fluvoxamine in patients with major depressive disorder

Recruiting
Phase of Trial: Clinical Phase Unknown

Latest Information Update: 10 May 2017

At a glance

  • Drugs Fluvoxamine (Primary)
  • Indications Major depressive disorder
  • Focus Pharmacogenomic; Therapeutic Use
  • Most Recent Events

    • 08 Aug 2008 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top